Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)USF: TrialNet UC4-3
1 型糖尿病数据协调中心 TrialNet (UC4)USF:TrialNet UC4-3
基本信息
- 批准号:9506924
- 负责人:
- 金额:$ 4264.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-22 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAwardBeta CellBiologicalBiological MarkersBiometryCharacteristicsClinicalClinical TrialsCommittee MembersCommunicationConduct Clinical TrialsContractsDataData AnalysesData CollectionData Coordinating CenterData QualityDevelopmentDiabetes MellitusDiabetes preventionDiagnosisDiseaseEnrollmentEnsureEpidemiologyFloridaFundingFutureGoalsGrantIndividualInsulinInsulin-Dependent Diabetes MellitusInterventionIntervention StudiesInvestigationLaboratoriesLeadMaintenanceManualsMethodologyMonitorNational Institute of Diabetes and Digestive and Kidney DiseasesNewly DiagnosedPaperPathogenesisPeriodicityPopulationPreparationPreventionPreventive InterventionProceduresProcessProtocols documentationPublicationsQuality ControlQuestionnairesRecordsRecruitment ActivityReportingRequest for ApplicationsResearchRiskRisk AssessmentRisk FactorsSafetySamplingSiteSpecimenStatistical Data InterpretationSystemTestingUniversitiesUpdateclinical research sitecost effectivenessdata managementdesigndiabetes riskfollow-upinnovationinsightinsulin dependent diabetes mellitus onsetinsulin secretionmeetingsnovel strategiesnovel therapeuticsoperationpreventprotocol developmentrepositoryresearch studyresponders and non-respondersresponsesymposiumtrial design
项目摘要
Project Summary/Abstract
This application requests support for the continuing operations of the TrialNet Coordinating
Center (TNCC) at the University of South Florida. The University of South Florida has served as
the Coordinating Center for TrialNet since October, 2008. The primary objective of TrialNet is to
prevent or delay initial onset and/or progression of type 1 diabetes (T1DM) by preserving
insulin-producing beta cells in individuals at elevated risk and those who have been newly
diagnosed with T1DM. To achieve this goal, TrialNet designs and implements prevention and
interventional clinical trials intended to test treatments that may preserve remaining insulin
secretion in recently diagnosed individuals (new-onsets). The TNCC provides epidemiological,
biostatistical, operational and administrative expertise and advice to the clinical centers,
reference laboratories and the NIDDK which include the following tasks: 1) study-wide
communications, procurement and dissemination of study materials, and related activities 2)
data management and records maintenance; 3) clinical site and central laboratories monitoring;
4) data analyses; 5) preparation of study reports and papers for publication; 6) implementation
of procedures to evaluate management, methodology, and cost-effectiveness of procedures
utilized by the TNCC; and 7) periodic meetings. This new application provides additional support
to focus on the design and conduct of new-onset trials (as selected by the TrialNet Steering
Committee) and associated mechanistic studies that can lead to targeted trials to prevent or
delay progression of T1D, provide enhancements and upgrades for communication, data
collection, editing, processing, analysis, and reporting for TrialNet studies and operations
including data quality, protocol adherence and data confidentiality, and provide for
implementation and upgrading of procedures for coordinating submission of samples and
data from the participating Clinical and Affiliate Centers to the TrialNet Central Laboratories
and NIDDK Repository.
项目总结/摘要
该应用程序请求支持审判网协调中心的持续运作。
中心(TNCC)在南佛罗里达大学。南佛罗里达大学曾担任
自2008年10月以来,审判网协调中心。TrialNet的主要目标是
预防或延迟1型糖尿病(T1 DM)的初始发作和/或进展,
胰岛素分泌β细胞在高风险个体和那些谁是新的
诊断为T1 DM。为了实现这一目标,TrialNet设计并实施了预防和
干预性临床试验,旨在测试可能保留剩余胰岛素的治疗
最近诊断的个体(新发)分泌。TNCC提供流行病学,
生物统计学、操作和管理专业知识以及对临床中心的建议,
参考实验室和NIDDK,包括以下任务:1)研究范围
交流、采购和分发学习材料以及相关活动2)
数据管理和记录维护; 3)临床研究中心和中心实验室监测;
4)数据分析; 5)编写研究报告和论文供出版; 6)执行
评价程序的管理、方法和成本效益的程序
由TNCC使用;和7)定期会议。此新应用程序提供了额外的支持
专注于设计和开展新的试验(由TrialNet指导委员会选定)
委员会)和相关的机制研究,可以导致有针对性的试验,以防止或
延迟T1 D的进展,提供通信、数据
为TrialNet研究和运行收集、编辑、处理、分析和报告
包括数据质量、方案依从性和数据保密性,并规定
执行和改进协调提交样品的程序,
从参与临床和附属中心到TrialNet中心实验室的数据
NIDDK Repository。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY P KRISCHER其他文献
JEFFREY P KRISCHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY P KRISCHER', 18)}}的其他基金
Limited Competition: Continued Follow-up of Subjects and Initiation of a Second Case-control Cohort in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
有限的竞争:在年轻研究中糖尿病的环境决定因素(TEDDY)中继续对受试者进行随访并启动第二个病例对照队列
- 批准号:
10398923 - 财政年份:2021
- 资助金额:
$ 4264.62万 - 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
- 批准号:
10403442 - 财政年份:2021
- 资助金额:
$ 4264.62万 - 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
- 批准号:
10179934 - 财政年份:2021
- 资助金额:
$ 4264.62万 - 项目类别:
Limited Competition: Continued Follow-up of Subjects and Initiation of a Second Case-control Cohort in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
有限的竞争:在年轻研究中糖尿病的环境决定因素(TEDDY)中继续对受试者进行随访并启动第二个病例对照队列
- 批准号:
10227415 - 财政年份:2021
- 资助金额:
$ 4264.62万 - 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
- 批准号:
10702185 - 财政年份:2021
- 资助金额:
$ 4264.62万 - 项目类别:
Follow-up on Subjects, Integrative Data Analysis and Measurement of Viral Antibodies in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
青年糖尿病环境决定因素研究(TEDDY)中的受试者跟踪、综合数据分析和病毒抗体测量
- 批准号:
10392400 - 财政年份:2020
- 资助金额:
$ 4264.62万 - 项目类别:
Follow-up on Subjects, Integrative Data Analysis and Measurement of Viral Antibodies in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
青年糖尿病环境决定因素研究(TEDDY)中的受试者跟踪、综合数据分析和病毒抗体测量
- 批准号:
10260891 - 财政年份:2020
- 资助金额:
$ 4264.62万 - 项目类别:
NIDDK Follow-up on Subjects and Immunological Assessments in The Environmental Determinants of Diabetes In The Young Study (TEDDY) (UC4)
NIDDK 青年糖尿病环境决定因素研究 (TEDDY) (UC4) 中受试者和免疫学评估的后续行动
- 批准号:
10088137 - 财政年份:2017
- 资助金额:
$ 4264.62万 - 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED) - DCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验 (MILED) - DCC
- 批准号:
10249943 - 财政年份:2016
- 资助金额:
$ 4264.62万 - 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED) - DCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验 (MILED) - DCC
- 批准号:
9743827 - 财政年份:2016
- 资助金额:
$ 4264.62万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 4264.62万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 4264.62万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 4264.62万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 4264.62万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 4264.62万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 4264.62万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 4264.62万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 4264.62万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 4264.62万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 4264.62万 - 项目类别:
Fellowship Programs